SCHEMBL17339166

SCHEMBL17339166

COC(=O)[C@H](C[C@@]1(C(=O)O)CCCC1=O)NC(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.38
TSHR P16473 3/20 0.38
MAPT P10636 2/20 0.38
CYP2C19 P33261 8/20 0.37
CYP3A4 P08684 5/20 0.37
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
NFKB1 P19838 1/20 0.32
PTGS2 P35354 1/20 0.32
THPO P40225 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28508861 0.89 CYP2C19 (0.37) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL18932721 0.89 CYP2C19 (0.37) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL18932722 0.86 CYP2C19 (0.44) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL28510350 0.86 CYP2C19 (0.44) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL4029333 0.86 CYP2C19 (0.44) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL17339215 0.85 CYP2C19 (0.34) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL4025300 0.82 CYP2C19 (0.41) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL18932720 0.76 TSHR (0.34) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL18918253 0.75 TSHR (0.40) CYP2C9TSHRMAPTCYP2C19CYP3A4
SCHEMBL17339206 0.75 TSHR (0.40) CYP2C9TSHRMAPTCYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10112973-B2 Process for the preparation of ramipril SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2018-10-30 US disclosed
EP-3154940-B1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI AVENTIS DEUTSCHLAND (DE) 2018-04-18 EP disclosed
US-20170158733-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2017-06-08 US disclosed
EP-3154940-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL Sanofi-Aventis Deutschland GmbH (DE) 2017-04-19 EP disclosed
WO-2015189108-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2015-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112973-B2 Process for the preparation of ramipril CYP2S1, CYP3A5, CYP4B1 CYP2C9 15/4885TSHR 2997/4885MAPT 2318/4885
US-20170158733-A1 PROCESS FOR THE PREPARATION OF RAMIPRIL CYP2S1, CYP3A5, CYP4B1 CYP2C9 15/4885TSHR 2997/4885MAPT 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.